skip to content
Integration of pharmaceutical discovery and development : case histories Preview this item
ClosePreview this item
Checking...

Integration of pharmaceutical discovery and development : case histories

Author: Ronald T Borchardt
Publisher: New York : Kluwer Academic, ©2002.
Series: Pharmaceutical biotechnology, v. 11.
Edition/Format:   eBook : Document : EnglishView all editions and formats
Summary:
[I]n the early 1990s a paradigm shift occurred in which drug design and development activities became more highly integrated. This new strategy required medicinal chemists to design drug candidates with structural features that optimized pharmacological (e.g., high affinity and specificity for the target receptor), pharmaceutical (e.g., solubility and chemical stability), biopharmaceutical (e.g., cell membrane
Rating:

(not yet rated) 0 with reviews - Be the first.

Subjects
More like this

 

Find a copy online

Find a copy in the library

&AllPage.SpinnerRetrieving; Finding libraries that hold this item...

Details

Genre/Form: Electronic books
Additional Physical Format: Print version:
Integration of pharmaceutical discovery and development.
New York : Kluwer Academic Publishers, ©2002
Material Type: Document, Internet resource
Document Type: Internet Resource, Computer File
All Authors / Contributors: Ronald T Borchardt
ISBN: 9780306473845 0306473844 0306457431 9780306457432
OCLC Number: 559205765
Description: 1 online resource (643 pages) : illustrations.
Contents: Renin Inhibitors --
The Discovery and Development of Angiotensin II Antagonists --
Development of an Orally Active Tripeptide Arginal Thrombin Inhibitor --
Discovery and Development of an Endothelin A Receptor-Selective Antagonist PD 156707 --
Endothelin Receptor Antagonists --
LHRH Antagonists --
LHRH Agonists --
Discovery and Development of Somatostatin Agonists --
Factors Impacting the Delivery of Therapeutic Levels of Pyrone-Based HIV Protease Inhibitors --
The Integration of Medicinal Chemistry, Drug Metabolism, and Pharmaceutical Research and Development in Drug Discovery and Development: The Story of Crixivan®, an HIV Protease Inhibitor --
De Novo Design and Discovery of Cyclic HIV Protease Inhibitors Capable of Displacing the Active-Site Structural Water Molecule --
Discovery and Development of the BHAP Nonnucleoside Reverse Transcriptase Inhibitor Delavirdine Mesylate --
Famciclovir: Discovery and Development of a Novel Antiherpesvirus Agent --
The Use of Esters as Prodrugs for Oral Delivery of Antibiotics --
Hematoregulators: A Case History of a Novel Hematoregulatory Peptide, SK&F 107647 --
Discovery and Development of GG745, a Potent Inhibitor of Both Isozymes of alpha-Reductase --Discovery of a Potent and Selective alpha <sub>IA Antagonist: Utilization of a Rapid Screening Method to Obtain Pharmacokinetic Parameters --
Discovery of Bioavailable Inhibitors of Secretory Phospholipase A2 --
The Anxieties of Drug Discovery and Development: CCK-B Receptor Antagonists --
CI-1015: An Orally Active CCK-B Receptor Antagonist with an Improved Pharmacokinetic Profile --
Orally Active Nonpeptide CCK-A Agonists --
Orally Active Growth Hormone Secretagogues --
Dorzolamide, a 40-Year Wait: From an Oral to a Topical Carbonic Anhydrase Inhibitor for the Treatment of Glaucoma --
Discovery and Development of Novel Melanogenic Drugs: Melanotan-I and -II --
Series Title: Pharmaceutical biotechnology, v. 11.
Responsibility: edited by Ronald T. Borchardt [and others].

Abstract:

In the late 1980s, it became painfully evident to the pharmaceutical industry that the old paradigm of drug discovery, which involved highly segmented drug - sign and development activities, would  Read more...

Reviews

User-contributed reviews
Retrieving GoodReads reviews...
Retrieving DOGObooks reviews...

Tags

Be the first.
Confirm this request

You may have already requested this item. Please select Ok if you would like to proceed with this request anyway.

Linked Data


Primary Entity

<http://www.worldcat.org/oclc/559205765> # Integration of pharmaceutical discovery and development : case histories
    a schema:MediaObject, schema:Book, schema:CreativeWork ;
    library:oclcnum "559205765" ;
    library:placeOfPublication <http://dbpedia.org/resource/New_York_City> ; # New York
    library:placeOfPublication <http://id.loc.gov/vocabulary/countries/nyu> ;
    schema:about <http://experiment.worldcat.org/entity/work/data/1044412025#Topic/medical_drug_guides> ; # MEDICAL--Drug Guides
    schema:about <http://experiment.worldcat.org/entity/work/data/1044412025#Topic/medical_nursing_pharmacology> ; # MEDICAL--Nursing--Pharmacology
    schema:about <http://id.worldcat.org/fast/898790> ; # Drugs--Design
    schema:about <http://experiment.worldcat.org/entity/work/data/1044412025#Topic/chemistry_pharmaceutical> ; # Chemistry, Pharmaceutical
    schema:about <http://id.worldcat.org/fast/898670> ; # Drug development
    schema:about <http://id.worldcat.org/fast/898940> ; # Drugs--Testing
    schema:about <http://id.loc.gov/authorities/subjects/sh85039755> ; # Drugs--Testing
    schema:about <http://id.loc.gov/authorities/subjects/sh88001157> ; # Drugs--Design
    schema:about <http://experiment.worldcat.org/entity/work/data/1044412025#Topic/medical_pharmacology> ; # MEDICAL--Pharmacology
    schema:about <http://dewey.info/class/615.19/e21/> ;
    schema:about <http://experiment.worldcat.org/entity/work/data/1044412025#Topic/drug_design> ; # Drug Design
    schema:about <http://experiment.worldcat.org/entity/work/data/1044412025#Topic/drug_evaluation> ; # Drug Evaluation
    schema:about <http://experiment.worldcat.org/entity/work/data/1044412025#Topic/medical_pharmacy> ; # MEDICAL--Pharmacy
    schema:bookFormat schema:EBook ;
    schema:contributor <http://viaf.org/viaf/64068053> ; # Ronald T. Borchardt
    schema:copyrightYear "2002" ;
    schema:datePublished "2002" ;
    schema:description "Renin Inhibitors -- The Discovery and Development of Angiotensin II Antagonists -- Development of an Orally Active Tripeptide Arginal Thrombin Inhibitor -- Discovery and Development of an Endothelin A Receptor-Selective Antagonist PD 156707 -- Endothelin Receptor Antagonists -- LHRH Antagonists -- LHRH Agonists -- Discovery and Development of Somatostatin Agonists -- Factors Impacting the Delivery of Therapeutic Levels of Pyrone-Based HIV Protease Inhibitors -- The Integration of Medicinal Chemistry, Drug Metabolism, and Pharmaceutical Research and Development in Drug Discovery and Development: The Story of Crixivan®, an HIV Protease Inhibitor -- De Novo Design and Discovery of Cyclic HIV Protease Inhibitors Capable of Displacing the Active-Site Structural Water Molecule -- Discovery and Development of the BHAP Nonnucleoside Reverse Transcriptase Inhibitor Delavirdine Mesylate -- Famciclovir: Discovery and Development of a Novel Antiherpesvirus Agent -- The Use of Esters as Prodrugs for Oral Delivery of Antibiotics -- Hematoregulators: A Case History of a Novel Hematoregulatory Peptide, SK&F 107647 -- Discovery and Development of GG745, a Potent Inhibitor of Both Isozymes of alpha-Reductase --Discovery of a Potent and Selective alpha IA Antagonist: Utilization of a Rapid Screening Method to Obtain Pharmacokinetic Parameters -- Discovery of Bioavailable Inhibitors of Secretory Phospholipase A2 -- The Anxieties of Drug Discovery and Development: CCK-B Receptor Antagonists -- CI-1015: An Orally Active CCK-B Receptor Antagonist with an Improved Pharmacokinetic Profile -- Orally Active Nonpeptide CCK-A Agonists -- Orally Active Growth Hormone Secretagogues -- Dorzolamide, a 40-Year Wait: From an Oral to a Topical Carbonic Anhydrase Inhibitor for the Treatment of Glaucoma -- Discovery and Development of Novel Melanogenic Drugs: Melanotan-I and -II --"@en ;
    schema:description "With this new, highly integrated approach to drug design now widely utilized by the pharmaceutical industry, the editors of this book have provided the scientific community with case histories to illustrate the nature of the interdisciplinary interactions necessary to successfully implement this new approach to drug discovery."--Page viii"@en ;
    schema:description "[I]n the early 1990s a paradigm shift occurred in which drug design and development activities became more highly integrated. This new strategy required medicinal chemists to design drug candidates with structural features that optimized pharmacological (e.g., high affinity and specificity for the target receptor), pharmaceutical (e.g., solubility and chemical stability), biopharmaceutical (e.g., cell membrane permeability), and metabolic/pharmacokinetic (e.g., metabolic stability, clearance, and protein binding) properties. Successful implementation of this strategy requires a multidisciplinary team effort, including scientists from drug design (e.g., medicinal chemists, cell biologists, enzymologists, pharmacologists) and drug development (e.g., analytical chemists, pharmaceutical scientists, physiologists, and molecular biologists representing the disciplines of pharmaceutics, biopharmaceutics, and pharmacokinetics/drug metabolism)."@en ;
    schema:exampleOfWork <http://worldcat.org/entity/work/id/1044412025> ;
    schema:genre "Electronic books"@en ;
    schema:inLanguage "en" ;
    schema:isPartOf <http://experiment.worldcat.org/entity/work/data/1044412025#Series/pharmaceutical_biotechnology> ; # Pharmaceutical biotechnology ;
    schema:isSimilarTo <http://worldcat.org/entity/work/data/1044412025#CreativeWork/integration_of_pharmaceutical_discovery_and_development> ;
    schema:name "Integration of pharmaceutical discovery and development : case histories"@en ;
    schema:productID "559205765" ;
    schema:publication <http://www.worldcat.org/title/-/oclc/559205765#PublicationEvent/new_york_kluwer_academic_2002> ;
    schema:publisher <http://experiment.worldcat.org/entity/work/data/1044412025#Agent/kluwer_academic> ; # Kluwer Academic
    schema:url <http://site.ebrary.com/id/10053277> ;
    schema:url <http://link.springer.com/10.1007/b114429> ;
    schema:url <http://www.netLibrary.com/urlapi.asp?action=summary&v=1&bookid=71180> ;
    schema:url <http://www.myilibrary.com?id=20821> ;
    schema:url <http://dx.doi.org/10.1007/b114429> ;
    schema:url <http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=71180> ;
    schema:url <http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=71180> ;
    schema:url <http://public.eblib.com/choice/publicfullrecord.aspx?p=3035726> ;
    schema:workExample <http://worldcat.org/isbn/9780306457432> ;
    schema:workExample <http://worldcat.org/isbn/9780306473845> ;
    wdrs:describedby <http://www.worldcat.org/title/-/oclc/559205765> ;
    .


Related Entities

<http://dbpedia.org/resource/New_York_City> # New York
    a schema:Place ;
    schema:name "New York" ;
    .

<http://experiment.worldcat.org/entity/work/data/1044412025#Agent/kluwer_academic> # Kluwer Academic
    a bgn:Agent ;
    schema:name "Kluwer Academic" ;
    .

<http://experiment.worldcat.org/entity/work/data/1044412025#Series/pharmaceutical_biotechnology> # Pharmaceutical biotechnology ;
    a bgn:PublicationSeries ;
    schema:hasPart <http://www.worldcat.org/oclc/559205765> ; # Integration of pharmaceutical discovery and development : case histories
    schema:name "Pharmaceutical biotechnology ;" ;
    .

<http://experiment.worldcat.org/entity/work/data/1044412025#Topic/chemistry_pharmaceutical> # Chemistry, Pharmaceutical
    a schema:Intangible ;
    schema:name "Chemistry, Pharmaceutical"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/1044412025#Topic/medical_drug_guides> # MEDICAL--Drug Guides
    a schema:Intangible ;
    schema:name "MEDICAL--Drug Guides"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/1044412025#Topic/medical_nursing_pharmacology> # MEDICAL--Nursing--Pharmacology
    a schema:Intangible ;
    schema:name "MEDICAL--Nursing--Pharmacology"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/1044412025#Topic/medical_pharmacology> # MEDICAL--Pharmacology
    a schema:Intangible ;
    schema:name "MEDICAL--Pharmacology"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/1044412025#Topic/medical_pharmacy> # MEDICAL--Pharmacy
    a schema:Intangible ;
    schema:name "MEDICAL--Pharmacy"@en ;
    .

<http://id.loc.gov/authorities/subjects/sh85039755> # Drugs--Testing
    a schema:Intangible ;
    schema:name "Drugs--Testing"@en ;
    .

<http://id.loc.gov/authorities/subjects/sh88001157> # Drugs--Design
    a schema:Intangible ;
    schema:name "Drugs--Design"@en ;
    .

<http://id.worldcat.org/fast/898670> # Drug development
    a schema:Intangible ;
    schema:name "Drug development"@en ;
    .

<http://id.worldcat.org/fast/898790> # Drugs--Design
    a schema:Intangible ;
    schema:name "Drugs--Design"@en ;
    .

<http://id.worldcat.org/fast/898940> # Drugs--Testing
    a schema:Intangible ;
    schema:name "Drugs--Testing"@en ;
    .

<http://viaf.org/viaf/64068053> # Ronald T. Borchardt
    a schema:Person ;
    schema:familyName "Borchardt" ;
    schema:givenName "Ronald T." ;
    schema:name "Ronald T. Borchardt" ;
    .

<http://worldcat.org/entity/work/data/1044412025#CreativeWork/integration_of_pharmaceutical_discovery_and_development>
    a schema:CreativeWork ;
    rdfs:label "Integration of pharmaceutical discovery and development." ;
    schema:description "Print version:" ;
    schema:isSimilarTo <http://www.worldcat.org/oclc/559205765> ; # Integration of pharmaceutical discovery and development : case histories
    .

<http://worldcat.org/isbn/9780306457432>
    a schema:ProductModel ;
    schema:isbn "0306457431" ;
    schema:isbn "9780306457432" ;
    .

<http://worldcat.org/isbn/9780306473845>
    a schema:ProductModel ;
    schema:isbn "0306473844" ;
    schema:isbn "9780306473845" ;
    .


Content-negotiable representations

Close Window

Please sign in to WorldCat 

Don't have an account? You can easily create a free account.